FeelTect

A great honour to end a wonderful Wounds Australia conference on beautiful Gold Coast - we received runner-up in the poster competition! It's been an excellent opportunity to connect with passionate members of Australia's #woundcare community over the last few days. Constant themes throughout the meeting were the benefits of virtual/digital care for wound care accessibility, and the importance of safe, effective #compressiontherapy in VLU treatment - aligning closely with FeelTect's core tenets. Thanks to the organisers for a top class conference, and thanks to Prof. Sebastian Probst for kindly sharing the picture of the announcement :) #TightAlright #connectedhealth #digitalhealth

All set to go! Team FeelTect is geared up for the first day of exhibition at Symposium on Advanced Wound Care (SAWC) Fall. We'd love to see anyone attending drop by for a chat at Booth 342. Put your compression skills to the test for a chance to win a tasty prize! 🦵 🩹 = 🏆 🥃

Exciting developments at FeelTect! 🎥 In this exclusive video interview, Andrew Cameron, founder of FeelTect, shares the story behind their award-winning Tight Alright technology, designed to revolutionise compression therapy for wound care. 🏆 Since winning the EWMA Innovation Competition in 2023, we were eager to learn what’s happened next. Key takeaways from the conversation include: 📋 Redefining guidelines with evidence-based data analytics to optimise compression therapy on an individual patient basis. 🏅 Impact of the EWMA Innovation Award: invaluable validation and media exposure. 💰 Investment attraction: The award played a key role in closing an investment round in late 2023. 🔍 Future focus: Clinical validation and health economic assessments. Don’t miss this insightful conversation! #Innovation #WoundCare #HealthTech #FeelTect #EWMA #EWMAInnovationAlliance #CompressionTherapy #Investment https://lnkd.in/dRNCTvfr

Another fantastic LSI meeting completed! It's been an insightful few days in beautiful Sintra, Portugal, meeting with investors, innovators, and industry insiders. I was proud to share FeelTect's achievements and promote our upcoming Series A fundraise. Looking forward to continuing engagements and developing partnerships for shared success!

Hot off the press! The latest edition of The Memo, featuring Andrew Cameron, Founder & CEO of FeelTect is out now. 🗞 Here’s a preview of this week’s edition of our weekly newsletter, The Memo: The Irish startup, led by Founder & CEO Andrew Cameron, is pioneering a new era in compression therapy for venous leg ulcers, aiming to improve patient outcomes and alleviate the burden on healthcare systems. The Current Landscape Venous leg ulcers continue to be a growing problem, particularly in aging populations and among individuals with comorbidities such as obesity. "In the last five years, the number of venous leg ulcers in the UK has doubled, and the healing rate has decreased by 20%," Cameron points out. This surge in cases is straining healthcare systems already burdened by limited resources and a shortage of trained nurses. Compression therapy has long been the standard of care for venous leg ulcers, a condition resulting from the breakdown of valves in the leg veins. This therapy, which dates back over 500 years, helps restore blood flow and heal wounds. However, its application remains fraught with challenges. "Compression is applied totally blind. There's a 90% failure rate to achieve targeted pressure in clinical practice. Too tight is dangerous, too loose is ineffective," Cameron explains. Nurses and caregivers often apply compression with little or no guidance leading to a lack of pressure measurement during application. "Only about 2% of patients are seen by trained tissue viability nurses," says Cameron. "Even if the pressure is applied correctly, it can lose up to 50% of its effectiveness within the first three days due to the reduction in swelling." This variability can lead to prolonged healing times and frequent recurrence of ulcers. Continue Reading: https://lnkd.in/grM6bnGg

We couldn’t have hoped for a better start to FeelTect’s latest clinical study with Home Wound Care! Yesterday marked the completion of our first recruited patient, who entered our study with a venous leg ulcer that hadn’t healed in over 8 months. After 8 weeks treatment with Tight Alright monitored compression therapy, the wound has completely healed! I’m not sure how common it is for the study team to receive flowers from a study participant but it definitely reflects our own appreciation for the work the team at Home Wound Care is doing. This gratitude is also what drives our ambition – to develop technology that delivers profound positive impacts for patients 😊. #woundcare #compressiontherapy #tightalright #connectedhealth

FeelTect (#LSIEurope24 Innovator) has developed Tight Alright, a pressure sensing, connected-health device for measuring and monitoring sub-bandage pressure during compression therapy, primarily for the millions of people worldwide with venous leg ulcers (VLUs). Compression is a proven therapy for VLUs however, if it’s applied too loose, it’s ineffective, and if it’s too tight, it’s dangerous. Tight Alright aims to improve the application and maintenance of evidence-based compression therapy, ensuring safety while reducing healing times. 🌟 FeelTect has recently achieved several major milestones including: • Closed a €1.2M seed round (June 2022) and a €1.8M pre-Series A round (December 2023). Looking to open a €3.5M Series A round in September 2024 to scale commercialization in USA, Germany, UK, and Switzerland. • Expanded the team with five new hires between Q4 2023 – Q1 2024, across technical, clinical and project management roles. • Won top prize of €10,000 at the European Wound Management Association (EWMA) Innovation Forum • Completed a clinical case series in the UK with Tight Alright guided treatment enabling up to 38.5% wound area reduction in just three weeks for patients with >12-month non-healing venous leg ulcers. • Commenced a multi-site pilot in Switzerland aimed at preparing the Tight Alright technology for Swiss reimbursement and first sales in patients treated with compression therapy. • Commenced enrollment of first patients in an 8-week cross-over study comparing the healing rates achieved using Tight Alright guided and monitored compression therapy, versus the standard of care. • Secured a €4.6M non-dilutive consortium grant to develop next generation of Tight Alright digital platform to include additional data inputs and modeling, for the first real-time, evidence-based clinical decision support system in wound care. • Registered the Tight Alright technology with FDA (Class I, 510K exempt) and CE Mark (Class I) for US and EU markets, respectively. We’re excited to announce that CEO, Dr. Andrew Cameron has been selected to present FeelTect at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Andrew and learn more about FeelTect.